Drug Profile
CT1 DAP001/DSP 1083
Alternative Names: Allo iPS cell-derived dopamine neural progenitor; Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells; CT1-DAP001; CT1-DAP001/DSP-1083; DSP-1083Latest Information Update: 10 May 2023
Price :
$50
*
At a glance
- Originator Sumitomo Dainippon Pharma
- Developer Sumitomo Pharma
- Class Induced pluripotent stem cell therapies; Neural stem cell therapies
- Mechanism of Action Dopaminergic cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Parkinson's disease